Lorenz Studer

Dec 9, 2024 | nature.com | Paola Arlotta |Helen S. Bateup |J. Gray Camp |Silvia Cappello |Fred Gage |Jürgen A. Knoblich | +13 more

AbstractAs the field of neural organoids and assembloids rapidly expands, there is an emergent need for guidance and advice on designing, conducting and reporting experiments to increase the reproducibility and utility of these models.

Sep 1, 2024 | nature.com | Juliane Tschuck |Gabriele Ciceri |Jason Tchieu |Brent R. Stockwell |Lorenz Studer |Michael P. Menden | +1 more

AbstractThe development of functional neurons is a complex orchestration of multiple signaling pathways controlling cell proliferation and differentiation. Because the balance of antioxidants is important for neuronal survival and development, we hypothesized that ferroptosis must be suppressed to gain neurons.

Jul 24, 2024 | nature.com | Yi-Hao Chan |zhiyong Liu |Paul Bastard |Oliver Harschnitz |Peng Zhang |Gabriele Ciceri | +14 more

AbstractMost cases of herpes simplex virus 1 (HSV-1) encephalitis (HSE) remain unexplained1,2. Here, we report on two unrelated people who had HSE as children and are homozygous for rare deleterious variants of TMEFF1, which encodes a cell membrane protein that is preferentially expressed by brain cortical neurons. TMEFF1 interacts with the cell-surface HSV-1 receptor NECTIN-1, impairing HSV-1 glycoprotein D- and NECTIN-1-mediated fusion of the virus and the cell membrane, blocking viral entry.

May 13, 2024 | nature.com | Nona Farbehi |Drew Neavin |Lorenz Studer

AbstractHuman pluripotent stem (hPS) cells can, in theory, be differentiated into any cell type, making them a powerful in vitro model for human biology. Recent technological advances have facilitated large-scale hPS cell studies that allow investigation of the genetic regulation of molecular phenotypes and their contribution to high-order phenotypes such as human disease.

Feb 20, 2024 | nature.com | Lorenz Studer

AbstractCD33 is a transmembrane receptor expressed on cells of myeloid lineage and regulates innate immunity. CD33 is a risk factor for Alzheimer’s disease (AD) and targeting CD33 has been a promising strategy drug development. However, the mechanism of CD33’s action is poorly understood. Here we investigate the mechanism of anti-CD33 antibody HuM195 (Lintuzumab) and its single-chain variable fragment (scFv) and examine their therapeutic potential.